Natixis Advisors LLC Acquires 16,210 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Natixis Advisors LLC boosted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 16.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 112,845 shares of the medical equipment provider’s stock after purchasing an additional 16,210 shares during the period. Natixis Advisors LLC’s holdings in Zimmer Biomet were worth $10,147,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. AMG National Trust Bank increased its stake in shares of Zimmer Biomet by 29.1% in the third quarter. AMG National Trust Bank now owns 50,359 shares of the medical equipment provider’s stock valued at $4,960,000 after buying an additional 11,339 shares during the period. Skandinaviska Enskilda Banken AB publ raised its position in shares of Zimmer Biomet by 47.5% during the third quarter. Skandinaviska Enskilda Banken AB publ now owns 62,079 shares of the medical equipment provider’s stock worth $6,115,000 after acquiring an additional 19,996 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Zimmer Biomet by 6.1% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 399,826 shares of the medical equipment provider’s stock worth $39,383,000 after acquiring an additional 22,992 shares during the period. Inceptionr LLC acquired a new position in shares of Zimmer Biomet in the third quarter worth approximately $1,217,000. Finally, Wilsey Asset Management Inc. bought a new stake in Zimmer Biomet in the fourth quarter valued at approximately $32,439,000. 88.89% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of analysts have weighed in on the stock. Truist Financial reissued a “hold” rating and set a $92.00 target price (down from $98.00) on shares of Zimmer Biomet in a research report on Wednesday, April 29th. Weiss Ratings raised shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Tuesday, April 7th. Wall Street Zen upgraded shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Robert W. Baird set a $92.00 target price on shares of Zimmer Biomet in a research note on Wednesday, April 29th. Finally, Barclays dropped their target price on shares of Zimmer Biomet from $100.00 to $94.00 and set an “underweight” rating on the stock in a report on Wednesday, April 29th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $102.70.

Zimmer Biomet Trading Up 0.2%

Shares of ZBH stock opened at $87.50 on Monday. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $79.12 and a fifty-two week high of $108.29. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.95 and a current ratio of 1.73. The stock has a 50 day simple moving average of $87.68 and a two-hundred day simple moving average of $90.49. The company has a market cap of $16.93 billion, a P/E ratio of 22.73, a PEG ratio of 2.02 and a beta of 0.47.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Tuesday, April 28th. The medical equipment provider reported $2.09 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.86 by $0.23. The firm had revenue of $2.09 billion for the quarter, compared to analysts’ expectations of $2.07 billion. Zimmer Biomet had a return on equity of 13.24% and a net margin of 9.05%.The company’s revenue for the quarter was up 9.3% compared to the same quarter last year. During the same period in the prior year, the business earned $1.81 EPS. Zimmer Biomet has set its FY 2026 guidance at 8.400-8.550 EPS. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.49 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 31st. Shareholders of record on Thursday, June 25th will be issued a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. The ex-dividend date is Thursday, June 25th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 24.94%.

Insiders Place Their Bets

In other news, insider Sang Yi sold 5,000 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $82.64, for a total transaction of $413,200.00. Following the transaction, the insider owned 27,251 shares of the company’s stock, valued at $2,252,022.64. This represents a 15.50% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Lori Winkler sold 2,650 shares of the firm’s stock in a transaction dated Thursday, March 12th. The shares were sold at an average price of $94.66, for a total value of $250,849.00. Following the completion of the sale, the senior vice president owned 10,224 shares of the company’s stock, valued at approximately $967,803.84. This represents a 20.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.28% of the company’s stock.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.